Kintor Pharma IPO: Valuation Insights
Kintor Pharmaceutical (9939 HK) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers and...
418 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
354 Views
Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK)Ā is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
558 Views
ECM Weekly (19 Apr 2020) - Kingsoft Cloud, Akesobio, Shenzhen Hepalink, China Gas, Yageo
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We are...
454 Views
COVID-19: A Brutal Lesson in Sustainability and Systemic ESG Risk
The COVID-19 pandemic is, above all else, a human health crisis. But it's a multidimensional crisis that serves as a poignant lesson in global...
608 Views